Xponance Inc. Has $2.45 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Xponance Inc. lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,027 shares of the medical equipment provider’s stock after purchasing an additional 1,083 shares during the period. Xponance Inc.’s holdings in Hologic were worth $2,453,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. FMR LLC raised its holdings in Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Boston Partners raised its stake in shares of Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after buying an additional 1,602,463 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after buying an additional 544,889 shares during the period. Raymond James Financial Inc. bought a new position in Hologic in the fourth quarter valued at approximately $27,007,000. Finally, Swedbank AB grew its holdings in Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after acquiring an additional 306,562 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. Royal Bank of Canada decreased their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research report on Thursday, February 6th. Evercore ISI cut their price target on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research report on Thursday, February 6th. Jefferies Financial Group assumed coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective for the company. Finally, Morgan Stanley cut their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Stock Up 0.8 %

HOLX stock opened at $61.47 on Friday. The business has a 50-day moving average of $66.06 and a 200-day moving average of $74.05. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The stock has a market capitalization of $13.79 billion, a P/E ratio of 19.39, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.